|
|
|
|
|
|
|
|
Gynecologic Oncology
The Oncologist first published on January 19, 2015; doi:10.1634/theoncologist.2014-0144
Borderline ovarian tumors
(BOTs) have been a challenge for patients, pathologists, and
oncologists. For the group of patients with invasive implants, there is
no consensus regarding standard therapy. This meta-analysis examines the
benefits, or lack thereof, of platinum-based adjuvant treatment for
BOT, showing that at present there is no evidence to support this
treatment form.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.